Solara Active Pharma Sciences (NSE:SOLARAPP) Debt-to-Equity : 0.77 (As of Sep. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Solara Active Pharma Sciences Debt-to-Equity?

Solara Active Pharma Sciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was ₹7,426 Mil. Solara Active Pharma Sciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was ₹973 Mil. Solara Active Pharma Sciences's Total Stockholders Equity for the quarter that ended in Sep. 2024 was ₹10,860 Mil. Solara Active Pharma Sciences's debt to equity for the quarter that ended in Sep. 2024 was 0.77.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Solara Active Pharma Sciences's Debt-to-Equity or its related term are showing as below:

NSE:SOLARAPP' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.39 Med: 0.67 Max: 1.08
Current: 0.77

During the past 8 years, the highest Debt-to-Equity Ratio of Solara Active Pharma Sciences was 1.08. The lowest was 0.39. And the median was 0.67.

NSE:SOLARAPP's Debt-to-Equity is ranked worse than
80.34% of 829 companies
in the Drug Manufacturers industry
Industry Median: 0.28 vs NSE:SOLARAPP: 0.77

Solara Active Pharma Sciences Debt-to-Equity Historical Data

The historical data trend for Solara Active Pharma Sciences's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Solara Active Pharma Sciences Debt-to-Equity Chart

Solara Active Pharma Sciences Annual Data

Trend

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Debt-to-Equity

Get a 7-Day Free Trial

0.67

0.39

0.68

1.08

Solara Active Pharma Sciences Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Debt-to-Equity	Get a 7-Day Free Trial															0.67	N/A	1.08	N/A	0.77

Competitive Comparison of Solara Active Pharma Sciences's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Solara Active Pharma Sciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Solara Active Pharma Sciences's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Solara Active Pharma Sciences's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Solara Active Pharma Sciences's Debt-to-Equity falls into.

Solara Active Pharma Sciences Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Solara Active Pharma Sciences's Debt to Equity Ratio for the fiscal year that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(8940.6	+	1174.4)	/	9339.1
	=	1.08

Solara Active Pharma Sciences's Debt to Equity Ratio for the quarter that ended in Sep. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(7426.3	+	973.2)	/	10860.2
	=	0.77

Solara Active Pharma Sciences (NSE:SOLARAPP) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Solara Active Pharma Sciences Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Solara Active Pharma Sciences's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Solara Active Pharma Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Solara Active Pharma Sciences Ltd (NSE:SOLARAPP) » Definitions » Debt-to-Equity

Traded in Other Exchanges

890202:India SOLARA:India 541540:India

Address

27, Vandaloor Kelambakkam Road, 2nd Floor. Admin Block, Melakottaiyur (Post), Keelakottaiyur Village, Chennai, TN, IND, 600 127

Website

https://www.solara.co.in

Solara Active Pharma Sciences Ltd is engaged in Active Pharmaceutical Ingredients manufacturer (API) in India. It manufactures and develops APIs and offers services, including CRAMS and contract manufacturing for APIs. The company offers products and services, such as Anaesthetic, Analgesics, Antiviral, Retinod, Anti-emetic, Antimalarial, Diuretic, Muscle relaxant, Antiallergics, Antihypertensive, Calcimimetic agent, Anti-seizure, Antigout, Cardiovascular, Anti-infective, Cough suppressant and others. It also offers contract services including contract development and manufacturing, analytical services. The group has a business presence in the Asia Pacific, Europe, North America, South America, and other places, of which the majority of income is generated from the Asia Pacific countries.

Solara Active Pharma Sciences Headlines

No Headlines